新春伊始，万象更新。2月25日，省委常委、市委书记盛阅春走访中央在汉单位和企 业、联系服务企业和春节期间不停工不停产企业，看望慰问一线工作人员。他强调，要深入 学习贯彻习近平总书记考察湖北重要讲话精神和中央经济工作会议精神，鼓足干劲、乘势而 上，全力抓生产、扩投资、优服务，奋力实现一季度"开门红、开门好"，为完成全年目标任 务打下坚实基础。 来到水利部长江水利委员会，盛阅春向大家致以新春问候，了解今年长江流域气候预 测、防洪抗旱形势等情况，并与长江委党组书记、主任廖志伟交流。他说，长期以来，长江 委扛牢长江大保护政治责任，有效指导我市流域防汛抗旱、水利规划设计、水生态文明建设 等工作，为保障江河安澜、人民安宁、城市安全作出了重要贡献。希望长江委一如既往指导 支持武汉开展长江保护与治理开发，共同谱写长江经济带高质量发展新篇章。 来到三峡集团，盛阅春代表市委、市政府感谢企业为武汉经济社会发展作出的重要贡 献，了解企业发展情况，与三峡集团总经理李富民就深化央地合作进行交流。他说，三峡集 团与武汉情谊深厚、合作基础良好，希望双方深化拓展在长江大保护、科技创新、清洁能 源、总部经济等领域合作，加强重大项目谋划，积极搭建 ...

证券代码：600998 证券简称：九州通 公告编号：临 2026-013 九州通医药集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 被担保人名称 | 本次担保 | 实际为其提供的担 保余额（不含本次 | 是否在前期 | 本次担保 | | --- | --- | --- | --- | --- | | | 金额 | | 预计额度内 | 是否有反 | | 广东九州通医 | | 担保金额） | | 担保 | | 药有限公司、安 | | | | | | 徽九州通医药 | 258,900.00 | 1,142,283.00 | 是 | 是 | | | 万元 | 万元 | | | | 有限公司等 36 | | | | | | 家子公司 | | | | | 累计担保情况 | 的总额不超过 亿元，截至 年 785.86 2026 1 | | --- | | 月 31 日，公司实际提供担保余额为 302.90 | | 亿元，主要为对控股子公司（含全资子公司 ...

Core Viewpoint - 九州通's subsidiary received approval for the listing application of Betahistine Dihydrochloride Tablets, which are used for Meniere's disease and cerebral vascular diseases, indicating potential growth in product offerings to meet aging population needs [1] Recent Events - 九州通 announced that its controlling shareholder, Chuchang Investment, has prematurely released the pledge of 11.3 million shares (2.46% of its holdings), while a related party, Shanghai Hongkang, pledged 11.7 million shares (1.08% of its holdings). As of the announcement date, the total pledged shares by Chuchang Investment accounted for 57.29% of its holdings and 26.03% of the company's total share capital [2] - The company is positioned as a digital service provider in the AI medical ecosystem, supporting the Ant Group's supply chain, with over 50 million orders in 2025, reflecting a 180% year-on-year increase [2] Stock Performance - As of February 12, 2026, 九州通's stock price was 5.21 yuan, with a cumulative decline of 1.14% over the past five days and a price fluctuation of 2.66%. The net outflow of main funds was 11.51 million yuan, with a turnover rate of 0.23%. The technical analysis indicates the stock is in a consolidation phase, with a 20-day moving average of 5.31 yuan, a Bollinger Band resistance level of 5.56 yuan, and a support level of 5.08 yuan [3] Institutional Viewpoints - The market is focusing on the integration of AI medical technology and pharmaceutical distribution digitalization. 九州通 is enhancing supply chain efficiency through smart warehousing and blockchain technology, with its pharmaceutical industrial business generating 2.3 billion yuan in revenue in the first three quarters of 2025, a year-on-year increase of 9.93%. However, there is uncertainty regarding the approval results for the newly accepted drugs [4]

证券代码：600998 证券简称：九州通 公告编号：临 2026-012 九州通医药集团股份有限公司 关于控股股东及其一致行动人提前解除股份质押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●截至2026年2月10日，公司控股股东楚昌投资及其一致行动人上海弘康分别持有公 司股份459,506,100股和1,088,326,782股，占公司总股本的比例分别为9.11%和21.58%。 本次股份提前解除质押及质押办理完成后，楚昌投资和上海弘康分别累计质押公司股份 187,350,980股和678,624,549股，占其所持股份的比例分别为40.77%和62.35%，占公司总 股本的比例分别为3.72%和13.46%。 ●截至2026年2月10日，控股股东楚昌投资及其一致行动人合计持有公司股份 2,290,962,492股，占公司总股本的比例为45.43%。本次股份提前解除质押及质押办理完 成后，控股股东楚昌投资及其一致行动人所持公司股份中已质押的股份总数为 1,312,536,405股，占其所持股份 ...

Core Viewpoint - The announcement indicates that the company’s subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., has received the acceptance notice for the marketing application of Betahistine Dihydrochloride Tablets from the National Medical Products Administration, which is a significant step towards product commercialization [2] Group 1 - The marketing application acceptance notice was issued on February 5, 2026 [2] - The product in question is Betahistine Dihydrochloride Tablets, which may have implications for the company's product portfolio and market strategy [2]

Group 1 - ZTE Corporation plans to invest 200 million RMB to subscribe to the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund, focusing on areas supported by national policies such as new generation information technology and biotechnology [1] - Huayi Jewelry's subsidiary has reported overdue loans totaling 200 million RMB due to tight liquidity, with a cumulative overdue principal of 254 million RMB [2] - Guangzhou Baiyunshan Pharmaceutical's subsidiary has received approval for the consistency evaluation of Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [3] Group 2 - Kunming Pharmaceutical Group reported a 21.72% decline in revenue to 6.577 billion RMB and a 46% drop in net profit to 350 million RMB for 2025 [4] - Jiantou Energy's application for a specific stock issuance has been approved by the Shenzhen Stock Exchange [5] - Jinchuan Titanium Industry's subsidiary has temporarily suspended its sulfuric acid production due to reduced demand [6] Group 3 - Kelun Pharmaceutical's subsidiary has received approval for a new indication for its antibody-drug conjugate, which is used to treat advanced hormone receptor-positive breast cancer [7] - Fawer Co., Ltd. has completed the relocation of its Chongqing Yuantai Shock Absorber Company and commenced production [8] - Jiuzhoutong's subsidiary has received acceptance for the listing application of Betahistine Hydrochloride tablets [9] Group 4 - Zhongguancun plans to build a traditional Chinese medicine and raw material drug production base in Jiamusi City, Heilongjiang Province [11] - China Wuyi announced that part of its land in Kenya has been requisitioned by the government, with compensation of approximately 6.25 million RMB [12] - Times Electric reported a 15.46% increase in revenue to 28.761 billion RMB and a 10.88% increase in net profit to 4.105 billion RMB for 2025 [13] Group 5 - Top Cloud Agriculture's shareholder has received regulatory measures from the Zhejiang Securities Regulatory Bureau for failing to timely disclose shareholding changes [14] - Xinwanda's subsidiary has reached a settlement in a lawsuit involving over 2.314 billion RMB, with an estimated impact of 500 to 800 million RMB on net profit for 2025 [15] - Dongrui Co., Ltd. reported a 25.19% increase in pig sales revenue in January, totaling 214 million RMB [16] Group 6 - Tianjin Tianshi reported a 3.08% decline in revenue to 8.236 billion RMB, while net profit increased by 15.68% to 1.105 billion RMB for 2025 [17] - Wantong Expressway plans to invest approximately 5.42 billion RMB in the renovation and expansion of the Lianhuo Expressway [18] - Qiaoyin Co., Ltd. has pre-qualified for a sanitation integration service project worth approximately 73.8 million RMB [20] Group 7 - Jindi Co., Ltd. plans to acquire 100% equity of Yuni Precision for 116 million RMB, focusing on precision stamping products [21] - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties [22] - Tongde Chemical has had some assets frozen due to a financing lease dispute [23] Group 8 - Zhongli Co., Ltd. is establishing an industrial fund with a total commitment of approximately 408.76 million RMB, focusing on new materials and artificial intelligence [24] - Tianbang Food reported a 9.93% increase in pig sales revenue in January, totaling 674 million RMB [25] - New Hope reported a 10.03% decrease in pig sales revenue in January, totaling 1.628 billion RMB [26] Group 9 - Tainkang's subsidiary has received a drug registration certificate for Minoxidil topical solution [27] - Lihua Co., Ltd. reported a 9.8% increase in chicken sales revenue in January, totaling 1.289 billion RMB [28] - Guojitong General reported a 45.71% increase in net profit to 58.52 million RMB for 2025 [29] Group 10 - Zhixin Co., Ltd. plans to invest up to 1.1 billion RMB in an automotive stamping and welding parts project [30] - Chuangyuan Technology's subsidiary has pre-qualified for a National Grid project worth approximately 94.77 million RMB [31] - Lisheng Pharmaceutical's adenine phosphate raw material has passed the listing application [32] Group 11 - Tongguang Cable's subsidiary has pre-qualified for a National Grid project worth approximately 108 million RMB [33] - Zhenghong Technology reported a 7.74% increase in pig sales revenue in January, totaling 14.35 million RMB [34] - Pengding Holdings reported a 0.07% decrease in consolidated revenue in January, totaling 2.701 billion RMB [35] Group 12 - Hongri Pharmaceutical has received approval for clinical trials of its injectable drug for acute pancreatitis [36][37] - Xinhua Medical has decided to terminate the acquisition of a 36.19% stake in Wuhan Zhongzhi Biotechnology [38] - Tianyu Bio reported an 11.23% decrease in pig sales revenue in January, totaling 54.29 million RMB [39]

Core Viewpoint - The approval of the listing application for Betahistine Dihydrochloride Tablets by the National Medical Products Administration is a significant milestone for the company, indicating potential growth in the neurology and cerebrovascular disease market [1] Group 1: Product Approval - The company's subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., received the acceptance notice for the listing application of Betahistine Dihydrochloride Tablets on February 5, 2026 [1] - Betahistine Dihydrochloride is primarily used for Ménière's disease, vascular headaches, and cerebral arteriosclerosis, and is effective in treating acute ischemic cerebrovascular diseases [1] - The drug is classified as a Category A medication under the national medical insurance and is included in the national essential drug list, addressing the high demand for dizziness-related conditions amid an aging population [1] Group 2: Business Performance - The company is actively expanding its pharmaceutical manufacturing and OEM business, focusing on increasing product variety and quality to enhance market competitiveness [1] - In the first three quarters of 2025, the company's pharmaceutical manufacturing and OEM business achieved sales revenue of 2.3 billion yuan, representing a year-on-year growth of 9.93% [1] - Beijing Jingfeng Pharmaceutical reported a revenue of 431 million yuan in the same period, with a year-on-year increase of 12.48% [1]

证券代码：600998 证券简称：九州通 公告编号：临 2026-011 关于子公司盐酸倍他司汀片上市申请收到国家药品监督管理局 《受理通知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 九州通医药集团股份有限公司（以下简称"公司"或"九州通"）控股子公 司北京京丰制药集团有限公司（以下简称"北京京丰"）于 2026 年 2 月 5 日收到 国家药品监督管理局核准签发的盐酸倍他司汀片上市申请《受理通知书》。现将 相关情况公告如下： 一、《受理通知书》主要内容 申请事项：境内生产药品注册上市许可 产品名称：盐酸倍他司汀片 规格：8mg；4mg 申请人：北京京丰制药集团有限公司 受理说明：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 九州通医药集团股份有限公司 二、药品相关情况 盐酸倍他司汀是一种类组胺药物，主要用于美尼尔综合征、血管性头痛及脑 动脉硬化，并可用于治疗急性缺血性脑血管疾病，如脑血栓、脑栓塞、一过性脑 供血不足等；对高血压所致直立性眩晕、耳鸣等亦有效。 盐酸倍他司汀片是国内神 ...

Group 1 - The core point of the article is that Jiuzhoutong announced the early release of share pledges by its controlling shareholder Chuchang Investment and its concerted action party Shanghai Hongkang, which holds significant shares in the company [1] - As of February 5, 2026, Chuchang Investment holds approximately 460 million shares, accounting for 9.11% of the total share capital, while Shanghai Hongkang holds about 1.088 billion shares, representing 21.58% of the total share capital [1] - After the completion of the early release and pledge handling, Chuchang Investment and Shanghai Hongkang have pledged approximately 199 million shares and 667 million shares respectively, which are 43.23% and 61.28% of their respective holdings, and 3.94% and 13.23% of the total share capital [1] Group 2 - The total number of pledged shares after the early release and pledge handling amounts to approximately 1.312 billion shares, which is 57.27% of the shares held by the controlling shareholders and 26.02% of the total share capital [1]

九州通医药集团股份有限公司 证券代码：600998 证券简称：九州通 公告编号：临 2026-010 关于控股股东及其一致行动人提前解除股份质押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●截至2026年2月5日，公司控股股东楚昌投资及其一致行动人上海弘康分别持有公 司股份459,506,100股和1,088,326,782股，占公司总股本的比例分别为9.11%和21.58%。 本次股份提前解除质押及质押办理完成后，楚昌投资和上海弘康分别累计质押公司股份 198,650,980股和666,924,549股，占其所持股份的比例分别为43.23%和61.28%，占公司总 股本的比例分别为3.94%和13.23%。 ●截至2026年2月5日，控股股东楚昌投资及其一致行动人合计持有公司股份 2,290,962,492股，占公司总股本的比例为45.43%。本次股份提前解除质押及质押办理完 成后，控股股东楚昌投资及其一致行动人所持公司股份中已质押的股份总数为 1,312,136,405股，占其所持股份的比 ...